The rationale was that commercial mydriatics administered during retinopathy of prematurity (ROP) screening have been ...

The Data and Safety Monitoring Board (DSMB) for the OCU410 ArMaDa clinical trial convened and approved continuation of the second phase of the Phase 1/2 study. The candidate being evaluated, OCU410 ...

Video content above is prompted by the following: Could you briefly provide an overview of the new treatments available for retinal vascular diseases?

Panelists discuss how the chronic nature of retinal diseases requires consistent VEGF suppression through regular anti-VEGF injections, but this treatment burden leads to challenges including patient ...

Panelists discuss how treat-and-extend dosing with aflibercept 2 mg allows for individualized treatment intervals while maintaining vision gains. However, optimal extension timing must be carefully ...

Panelists discuss how the port delivery system (PDS) is a permanent, refillable ocular implant that continuously releases ranibizumab into the vitreous, with the Archway trial demonstrating ...

A large international study conducted by the LHON Study Group reported that a unilaterally administered gene therapy to treat Leber hereditary optic neuropathy (LHON) caused by the MT-ND4 gene variant ...